Fuchs’ corneal dystrophy

Eghrari, Allen O.; Gottsch, John D.

doi:10.1586/eop.10.8

Cited by 107 publications

(71 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[47][48][49] When endothelial cell density decreases significantly, from the average of 3000 to nearly 1000 cells/mm 2 (as in Fuchs' dystrophy) their function is compromised, corneal transparency is lost and surgery is required. 50 There are promising therapies for corneal endothelium repair and wound healing, including the arrest of cell loss, endothelial cell transplantation, and stimulation of fluid secretion by the remaining endothelial cells. 3,51 Nevertheless, keratoplasty remains the main treatment to repair this layer.…”

Section: Corneal Endothelium Physiologymentioning

confidence: 99%

See 1 more Smart Citation

Corneal endothelium: developmental strategies for regeneration

Zavala

Jaime

Barrientos

et al. 2013

Eye

114

View full text Add to dashboard Cite

The main treatment available for restoration of the corneal endothelium is keratoplasty. This procedure is faced with several difficulties, including the shortage of donor tissue, postsurgical complications associated with the use of drugs to prevent immune rejection, and a significant increase in the occurrence of glaucoma. Recently, surgical procedures such as Descemet's stripping endothelial keratoplasty have focused on the transplant of corneal endothelium, yielding better visual results but still facing the need for donor tissue. The emergent strategies in the field of cell biology and tissue cultivation of corneal endothelial cells aim at the production of transplantable endothelial cell sheets. Cell therapy focuses on the culture of corneal endothelial cells retrieved from the donor, in the donor's cornea, followed by transplantation into the recipient. Recently, research has focused on overcoming the challenge of harvesting human corneal endothelial cells and the generation of new biomembranes to be used as cell scaffolds in surgical procedures. The use of corneal endothelial precursors from the peripheral cornea has also demonstrated to be effective and represents a valuable tool for reducing the risk of rejection in allogeneic transplants. Several animal model reports also support the use of adult stem cells as therapy for corneal diseases. Current results represent important progresses in the development of new strategies based on alternative sources of tissue for the treatment of corneal endotheliopathies. Different databases were used to search literature: PubMed, Google Books, MD Consult, Google Scholar, Gene Cards, and NCBI Books. The main search terms used were: 'cornea AND embryology AND transcription factors', 'human endothelial keratoplasty AND risk factors', '(cornea OR corneal) AND (endothelium OR endothelial) AND cell culture', 'mesenchymal stem cells AND cell therapy', 'mesenchymal stem cells AND cornea', and 'stem cells AND (cornea OR corneal) AND (endothelial OR endothelium)'.

show abstract

Section: Corneal Endothelium Physiologymentioning

confidence: 99%

“…3,51 Nevertheless, keratoplasty remains the main treatment to repair this layer. 48,50 The complications associated with this make the treatment of endotheliopathies a challenge for current and future research.…”

Section: Corneal Endothelium Physiologymentioning

confidence: 99%

Corneal endothelium: developmental strategies for regeneration

Zavala

Jaime

Barrientos

et al. 2013

Eye

114

View full text Add to dashboard Cite

show abstract

“…11 Another possibility, however, is that a gradual increase in CCT arises as FECD progresses. Studies have been limited in their ability to distinguish between these mechanisms due to a lack of standardization of grading criteria, small sample sizes and a lack of prospective studies.…”

Section: Commentmentioning

confidence: 99%

“…Thickening is believed to occur mainly in the later stages of FECD, manifesting as clinically apparent stromal and/or epithelial edema. 11, 12 The relationship between earlier stages of FECD and CCT is less clear. Prior studies have been limited by small samples sizes, a lack of consistent definitions of FECD severity and by heterogeneous FECD study populations.…”

Section: Introductionmentioning

confidence: 99%

Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

et al. 2012

View full text Add to dashboard Cite

“…FECD results in corneal edema, severe impairment of visual acuity, may lead to blindness , and is a leading indication for corneal transplantation (Eye Bank Association of America 2012). Clinically, two forms of FECD have been identified: a rare early-onset form of FECD that starts in the first decade of life, and progresses through the second and third decades (Magovern et al 1979), and the more common late-onset form of FECD progresses through four clinically defined stages that span a period of two-to-three decades (Eghrari and Gottsch 2010). Corneal transplantation is the only treatment modality to restore lost vision in patients affected with advanced FECD.…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms of the Apoptosis-Related FAS and FAS Ligand Genes in Keratoconus and Fuchs Endothelial Corneal Dystrophy

Synowiec

Wójcik

Izdebska

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Keratoconus (KC) is a non-inflammatory eye disease characterized by progressive corneal thinning and asymmetrical conical protrusion of the cornea. Fuchs endothelial corneal dystrophy (FECD) is a degenerative, slowly progressive disease of the corneal endothelium that is characterized by alteration in corneal endothelial cell morphology and progressive loss of these cells. They are unrelated eye diseases that may ultimately lead to vision loss. Their pathogenesis is largely unknown, although impaired apoptosis has been suggested to be responsible for both diseases. Therefore, we studied the frequency of the c.-671A>G polymorphism of the apoptosis-related FAS gene and the c.-844T>C polymorphism of the FAS ligand (FASLG) gene in patients with FECD (221 individuals) or KC (264) and controls (300). Each polymorphism is located within the putative cis-acting element of the respective promoter. Risk of KC or FECD was estimated with unconditional multiple logistic regression with adjustment for various factors, including age, sex, allergies, and family history. The T/T genotype and the T allele of the c.-844T>C polymorphism were associated with increased occurrence of KC, while the C allele was associated with decreased KC occurrence. The G allele of the c.-671A>G polymorphism was associated with increased occurrence of FECD, while the A allele was associated with decreased FECD occurrence. The C/C-A/A combined genotype was associated with reduced risk of FECD, whereas the T/T-G/A combined genotype increased risk of KC. In conclusion, variability in the expression of the FAS and FASLG genes may be involved in the pathogenesis of KC and FECD.

show abstract

Fuchs’ corneal dystrophy

Cited by 107 publications

References 122 publications

Corneal endothelium: developmental strategies for regeneration

Corneal endothelium: developmental strategies for regeneration

Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

Polymorphisms of the Apoptosis-Related FAS and FAS Ligand Genes in Keratoconus and Fuchs Endothelial Corneal Dystrophy

Contact Info

Product

Resources

About